We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+39.45%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$1.29B
AUM Growth
+$497M
Cap. Flow
+$278M
Cap. Flow %
21.56%
Top 10 Hldgs %
61.71%
Holding
54
New
8
Increased
22
Reduced
6
Closed
11

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$51.1M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$44.7M
3
IMMU
Immunomedics Inc
IMMU
+$42.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$39.4M
5
PCRX icon
Pacira BioSciences
PCRX
+$34M

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$43.2M
2
TSRO
TESARO, Inc.
TSRO
+$25.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$17.1M
4
AERI
Aerie Pharmaceuticals
AERI
+$12.1M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 67.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$206M 15.98%
14,739,461
+4,251,385
+41% +$42.4M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$97.1M 7.53%
6,437,122
+506,166
+9% +$6.7M
KITE
3
DELISTED
Kite Pharma, Inc.
KITE
$89.4M 6.93%
496,983
-309,767
-38% -$43.2M
ARRY
4
DELISTED
Array Biopharma Inc
ARRY
$65.8M 5.11%
5,353,029
+1,177,653
+28% +$10.9M
CLVS
5
DELISTED
Clovis Oncology, Inc.
CLVS
$64.7M 5.02%
785,700
+645,000
+458% +$51.1M
MDCO
6
DELISTED
Medicines Co
MDCO
$63.7M 4.94%
1,720,393
+611,293
+55% +$22.5M
ASND icon
7
Ascendis Pharma A/S
ASND
$16.5B
$59.3M 4.6%
1,636,124
+645,200
+65% +$18.5M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.9B
$55.7M 4.32%
597,972
+97,183
+19% +$8.59M
PCRX icon
9
Pacira BioSciences
PCRX
$1.04B
$49.2M 3.82%
1,311,460
+845,642
+182% +$34M
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$44.6M 3.46%
+3,516,100
New +$44.7M
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$43.4M 3.37%
3,710,601
+1,435,200
+63% +$8.3M
AVXS
12
DELISTED
AveXis, Inc. Common Stock
AVXS
$42.2M 3.28%
+436,702
New +$39.4M
DERM
13
DELISTED
Dermira, Inc.
DERM
$41M 3.18%
1,520,000
+195,000
+15% +$5.1M
ZGNX
14
DELISTED
Zogenix, Inc.
ZGNX
$36M 2.79%
+1,026,368
New +$13.9M
GBT
15
DELISTED
Global Blood Therapeutics, Inc.
GBT
$34.9M 2.71%
1,124,300
+264,300
+31% +$7.43M
IOVA icon
16
Iovance Biotherapeutics
IOVA
$2.04B
$32.6M 2.53%
4,201,343
+50,000
+1% +$316K
ASMB icon
17
Assembly Biosciences
ASMB
$498M
$31.7M 2.46%
75,597
+25,000
+49% +$7.66M
TLGT
18
DELISTED
Teligent, Inc
TLGT
$30.7M 2.38%
457,823
+44,743
+11% +$3.28M
TSRO
19
DELISTED
TESARO, Inc.
TSRO
$25.2M 1.95%
195,092
-205,311
-51% -$25.5M
INDP icon
20
Indaptus Therapeutics
INDP
$243M
$19.7M 1.52%
+980
New +$14.1M
VNDA icon
21
Vanda Pharmaceuticals
VNDA
$304M
$17.7M 1.37%
988,270
+86,124
+10% +$1.44M
AVEO
22
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$17.5M 1.36%
480,625
-182,620
-28% -$5.65M
MYOK
23
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$17.1M 1.32%
+398,207
New +$12.7M
CPRX
24
DELISTED
Catalyst Pharmaceutical
CPRX
$11.7M 0.91%
4,635,745
+831,000
+22% +$2.28M
AGEN
25
Agenus
AGEN
$276M
$10.8M 0.84%
125,314
-36,902
-23% -$2.99M
1
2 3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Avoro Capital Advisors held 54 positions worth $1.29B, up 63% from $792M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Avoro Capital Advisors deployed $278M of net new capital in Q3 2017, opening 8 new positions and adding to 22 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 3,516,100 shares worth $44.6M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 65% a quarter earlier.

On the sell side, the largest reduction was Kite Pharma, Inc., an estimated $43.2M trimmed.

  • Avoro Capital Advisors's largest Q3 2017 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 3,516,100 shares worth $44.6M.
  • Avoro Capital Advisors added most to Clovis Oncology, Inc. in Q3 2017, an estimated $51.1M increase.
  • Avoro Capital Advisors's biggest Q3 2017 reduction was Kite Pharma, Inc., cutting an estimated $43.2M.
  • Avoro Capital Advisors fully exited Acadia Pharmaceuticals in Q3 2017, selling an estimated $17.1M.
  • Avoro Capital Advisors's ten largest holdings make up 62% of its $1.29B portfolio in Q3 2017.
  • Avoro Capital Advisors opened 8 new positions and closed 11 in Q3 2017.
  • Avoro Capital Advisors's portfolio value rose 63% quarter-over-quarter to $1.29B.

Based on Avoro Capital Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.